DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages


Biological agents for psoriasis

Author: Vanessa Ngan, Staff Writer, 2003. Updated by Chief Editor: Hon Assoc Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, February 2015. Copy edited by Gus Mitchell. April 2018.


What are biological agents?

Biological agents or treatments, also known as biologics, biologic therapies, or biological response modifiers, are drugs derived from living material (human, plant, animal, or microorganism). They interfere with specific parts of the body's immune system to treat and prevent immune-mediated inflammatory disorders and cancers. They are also called targeted therapies.

Biological agents for psoriasis

Biological agents approved for the treatment of psoriasis include:

Efalizumab (Raptiva®) was withdrawn from the market in 2009 and Alefacept (Amevive®) was withdrawn from the market in 2011.

The biological agent medications used for psoriasis are also used for other severe health problems. Registered indications in New Zealand in October 2019 are shown below.






How do biological agents work in psoriasis?

Psoriasis is a disorder of the immune system. In psoriasis, abnormally large numbers of T cells trigger the release of cytokines that cause inflammation, redness, itching and flaky skin patches.

Biological agents work by interfering with specific components of the autoimmune response. Unlike general immunosuppressants that suppress the entire immune system, biological agents can fight more selectively and target only those chemicals involved in causing psoriasis.

Etanercept, infliximab and adalimumab belong to the class of biological medicines called tumour necrosis factor-alpha (TNFα) blockers. These work by blocking the activity of TNFα, the primary cytokine involved in psoriasis. Ustekinumab targets interleukin-12 (IL-12) and IL-23. Guselkumab and tildrakizumab target IL 23. Secukinumab, ixekinumab, brodalumab, and bimekizumab target IL-17.

The biological agents whose names end in 'mab' are monoclonal antibodies. Etancercept is a fusion protein.

How are biological agents given for psoriasis?

All these biological medicines are given at defined intervals. The interval between doses is dependent on each individual biological medicine. Etanercept, alefacept and efalizumab are usually once weekly, and adalimumab is every two weeks by self-administered subcutaneous injection. Infliximab is given by intravenous infusion at a hospital or clinic, 3 times over a period of 6 weeks and then every 8 weeks.

In many cases, other topical and systemic medications for psoriasis (eg, methotrexate) may also be prescribed in an attempt to improve efficacy.

Biological medication is often very effective in psoriasis. However, in some cases, they lose their effectiveness after a period of time (secondary failure) and other treatment may be required.

What are the possible side effects of biological agents?

To date, biological agents for psoriasis appear to have very few side effects. Because of their precise targets, they appear not to damage the entire immune system the way that general immunosuppressants do. However, biological agents should still be considered immunosuppressive and may increase the risk of infection and reactivation of tuberculosis (TB). Uncommon infections with organisms such as listeria and legionella may be more common and more serious in patients on biological agents. Infections are more common in older patients on biologics. 

Screening for latent TB and other infections (hepatitis B, HIV and others) should be undertaken prior to commencing a TNFα inhibitor and other biological agents.

Biological agents may also increase the risk of skin cancer, especially squamous cell carcinoma (SCC) and some lymphomas

On the other hand, mortality may be reduced in patients taking TNFα inhibitors compared to that in patients with psoriasis that are not taking them. This is due to a marked reduction in myocardial infarction. Some of the newer biological agents may also be associated with lower rates of malignancy than arise in matched patients that are not taking them.

When should biological agents be used?

Due to the high cost of these medicines, their use is limited to patients with moderate to severe psoriasis where:

  • All other treatments have failed
  • Side effects of other treatments become intolerable or toxicity has occurred
  • Concurrent diseases such as congestive heart failure or liver disease preclude the use of currently available systemic therapies.

In New Zealand, infliximab, adalimumab, etanercept and secukinumab are funded by PHARMAC for some cases of severe psoriasis on Special Authority application.

Vaccinations and biological agents

Immunisation status should be reviewed prior to starting treatment with biological agents. If necessary, vaccines should be updated prior to treatment. Annual influenza vaccination is recommended.

As they may induce illness in immunodeficient individuals, live vaccines should not be used during treatment with biological agents. Currently-available live attenuated viral vaccines include measles, mumps, rubella, varicella, yellow fever, the intranasal form of influenza vaccine, and the oral polio vaccine. Live attenuated bacterial vaccines include BCG and oral typhoid vaccine.

Read more about immunisation in immunosuppressed dermatology patients.

Monitoring while on biological agents

It is recommended that patients on biological medications should be monitored, and should have routine blood tests at least every 6 months or so, including full blood count and liver function tests. Screening for latent TB should be repeated from time to time.

The future of biological agents

Research and development in the field of biological agents for psoriasis for treating psoriasis in 2015 include:

  • AMG-827 and ixekinumab (IL-17 inhibitors)
  • Certolizumab (a humanised monoclonal antibody used in Crohn disease).

Biological agents for other types of skin disease

Other biological agents used for severe skin diseases (January 2018) include:

There are many other promising biological agents under investigation for skin conditions.

Approved datasheets are the official source of information for medicines, including approved uses, doses, and safety information. Check the individual datasheet in your country for information about medicines.

We suggest you refer to your national drug approval agency such as the Australian Therapeutic Goods Administration (TGA), US Food and Drug Administration (FDA)UK Medicines and Healthcare products regulatory agency (MHRA) / emc, and NZ Medsafe, or a national or state-approved formulary eg, the New Zealand Formulary (NZF) and New Zealand Formulary for Children (NZFC) and the British National Formulary (BNF) and British National Formulary for Children (BNFC).



  • Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003;49(2 Suppl):S44-S50. doi:10.1016/s0190-9622(03)01134-4. PubMed
  • Menter MA, Krueger GC, Feldman SR, Weinstein GD. Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol. 2003;49(2 Suppl):S39-S43. doi:10.1016/mjd.2003.545. PubMed
  • Boehncke WH. Immunomodulatory drugs for psoriasis. BMJ. 2003;327(7416):634-5. doi:10.1136/bmj.327.7416.634. PubMed
  • Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 [published correction appears in Br J Dermatol. 2005 Nov;153(5):1092. Grifitths, C E M [corrected to Griffiths, C E M]]. Br J Dermatol. 2005;153(3):486-97. doi:10.1111/j.1365-2133.2005.06893.x. PubMed
  • Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535. doi:10.1002/14651858.CD011535.pub3. PubMed
  • Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690. doi:10.3390/ijms21051690. PubMed

On DermNet

Books about skin diseases


Related information

Sign up to the newsletter